ABSTRACT Hepatocyte growth factor (HGF) suppresses FSH-dependent estradiol-17␤ (E 2 ) production in ovarian granulosa cells (GC).
INTRODUCTION
Follicle-stimulating hormone directs granulosa cell (GC) differentiation into estrogenic cells. This process enables GC to convert theca cell androgens into estradiol-17␤ (E 2 ). Bioactivity of FSH is itself mediated by cAMP-dependent signal transduction [1] . The FSH-cAMP-dependent signaling supports the expression and function of the estrogenic enzymes in GC:cytochrome P450 aromatase (P450arom) and 17␤-hydroxysteroid dehydrogenase type-1 (17␤-HSD) [2] . The P450arom and 17␤-HSD orchestrate FSH-depen- dent conversion of androgens into estrone (E 1 ) and E 2 , respectively.
Bioactivity of FSH in GC is subject to modulation by intraovarian cytokines [3] . Hepatocyte growth factor (HGF) shows promise as one such regulatory intraovarian cytokine. Hepatocyte growth factor was initially characterized due to its mitogenic and motogenic actions in hepatocyte cultures [4] . Hepatocyte growth factor protein has been measured in human follicular fluid [5] , and HGF mRNA has been detected in GC and theca cells obtained from immature rat ovaries [6] . Hepatocyte growth factor is part of an autocrine/paracrine system that exerts multiple levels of control within GC and theca cells [7] . For example, HGF blocks LH-dependent androgen production by theca cells [6] . Moreover, HGF stimulates bovine GC mitosis [8] but impairs the FSH-dependent conversion of androstenedione into E 2 in vitro [9, 10] .
Although HGF can mediate GC growth and steroidogenesis, virtually nothing is known regarding how HGF functions in GC. One study has shown that HGF suppresses P450arom activity in bovine and diethylstilbestrol (DES)-primed rat GC in vitro [9] ; implying that the conversion of androstenedione into E 1 is selectively blocked by HGF. The comparative effects of HGF on E 1 and E 2 production, as well as any effects of HGF upon P450arom and 17␤-HSD expression, would enable more complete understanding about how HGF alters the estrogen biosynthetic pathway in GC.
The HGF receptor, c-Met, is expressed in GC [11] . In isolated bovine follicles, c-Met mRNA accumulation increased relative to follicle size [9] . Therefore, it appears as if c-Met expression is hormonally regulated during folliculogenesis; moreover, it is likely that changes in c-Met expression dictate GC responsiveness to HGF. To date, the temporal and hormonal regulation of c-Met expression in GC has not been directly tested.
In nonovarian cells, HGF binding and activation of the c-Met tyrosine kinase induces a complex array of phospholipid-dependent signal transduction [7] . This signaling motif incorporates the stimulation of one or more c-Akt/protein kinase B isozymes (PKB␣, ␤, and ␥) [12] . Because this HGF-PKB-dependent signaling pathway has been observed, it is possible that similar mechanisms may function in HGF-stimulated GC.
By determining changes in the expression of c-Met and HGF signaling molecules (i.e., PKB) in GC, we can begin to elaborate upon how HGF blocks FSH-dependent E 2 production. In this study, HGF-and FSH-stimulated alterations in the estrogen biosynthetic pathway are compared with changes in the relative abundance of both c-Met and PKB mRNA expression in GC. 
MATERIALS AND METHODS

Reagents and Supplies
Recombinant human HGF (lyophilized with BSA as a carrier, 97% purity) was purchased from R&D Systems (Minneapolis, MN). Human recombinant FSH was generously donated by the National Hormone and Pituitary Program of the NIDDK and Dr. Parlow (Harbor-UCLA, Torrance, CA). McCoy's 5a medium (M5a, serum-free) and Medium 199 were purchased from GIBCO-BRL (Grand Island, NY). Oligonucleotide polymerase chain reaction (PCR) primers were synthesized by GIBCO-BRL. Culture plates were purchased from Falcon (Lincoln Park, NJ).
[␣32P]dCTP (3000 Ci/mmol) was obtained from Dupont NEN (Boston, MA). The E 2 and E 1 RIA kits were obtained from Diagnostic Products Corporation (Los Angeles, CA) and Diagnostic Systems Laboratories (Webster, TX), respectively. Microcarrier was generously donated by Molecular Research Products, Inc. (Cincinnati, OH). Unless otherwise specified, all assay reagents were purchased from Sigma (St. Louis, MO), and reverse transcription (RT)-PCR reagents were purchased from Perkin Elmer Cetus (Foster City, CA).
Granulosa Cell Culture
All animal procedures were approved by the SIU-Edwardsville Institutional Animal Care and Use Committee. Immature (25-27-day-old) Sprague-Dawley rats (SASCO, Wilmington, MA) were euthanized via CO 2 inhalation followed by cervical dislocation. Ovaries were removed and placed in ice-cold Medium 199 supplemented with 0.1% BSA (containing PSG: penicillin, 100 U/ml; streptomycin sulfate, 100 g/ml; and L-glutamine, 2 mM). Ovaries were cleaned of bursa and other extraneous tissues, and GC were collected from the surrounding media following follicle puncture. Granulosa cells were centrifuged (250 ϫ g), then resuspended in a known volume of M5a that was supplemented with PSG. Granulosa cell number and viability were determined by trypan blue exclusion using a hemacytometer.
Aliquots of GC (1 ϫ 10 5 viable cells/well) were placed in 24-well culture plates. All GC were incubated in a final volume of 500 l M5a/well containing 0.1 M androstenedione, and GC identified as controls in this report did not receive treatments in addition to androstenedione. Designated GC were given FSH (0.3, 3.0, or 30 ng/ml) with or without HGF (30 ng/ml). The HGF concentration was chosen in order to approximate the reported K d (0.3 nM) for HGF binding [4] , as well as HGF concentrations measured in human follicular fluid [5] . The effect of HGF on dibutyryl-cAMP (Bu 2 -cAMP) steroidogenic differentiation was investigated by challenging GC with Bu 2 -cAMP (50, 100, and 250 M), in the presence and absence of HGF (30 ng/ ml). Cultures were conducted at 37ЊC in a humidified atmosphere containing 5% CO 2 in air.
Incubations to measure E 1 and E 2 production were terminated at 48 h. The GC-conditioned media were collected and frozen at Ϫ20ЊC pending RIA to measure E 1 and E 2 content. Radioimmunoassays were conducted according to the kit manufacturers' protocols.
Reverse Transcription-Polymerase Chain Reaction
To measure the relative level of P450arom, 17␤-HSD, and c-Met mRNAs, GC were incubated for either 48 h (17␤-HSD and P450arom), or 12, 24, 36, and 48 h (c-Met), in the presence and absence of FSH (0.3, 3.0, or 30 ng/ml), HGF (30 ng/ml), or Bu 2 -cAMP (100, 250, or 500 M). For analysis of PKB␣ mRNA content, GC were cultured with FSH or HGF for 12, 24, 36, and 48 h. An aliquot of GC was frozen immediately upon harvest from the follicles (t ϭ 0 GC) in order to establish basal levels of c-Met and PKB␣ mRNAs.
The RT-PCR procedures were based upon the initial methods described by Orly et al. [13] . In brief, upon collection of the GC-conditioned media for measurement of estrogen content, the RNA extraction was performed using Trizol reagent containing 5 l microcarrier per well. The RNA was resuspended in diethyl pyrocarbonate-treated MilliQ H 2 O. The RNA samples from duplicate treatment groups were pooled and RNA concentration was measured at A 260 . The RNA was stored at Ϫ80ЊC pending RT-PCR.
Aliquots of RNA (1 g RNA/reaction) were used as templates for the synthesis of cDNA in reactions containing 1ϫ PCR buffer II, 0.5 mM dNTPs, 100 ng oligo (dT) [12] [13] [14] [15] [16] [17] [18] , 1 U/ l recombinant placental RNase inhibitor, 200 U M-MLV reverse transcriptase, and 4 mM MgCl 2 . After incubation at 37ЊC for 30 min, the reaction was heat inactivated at 95ЊC for 5 min and then cooled to 22ЊC. Specific cDNA primers (10-50 pmol) for P450arom [14] , c-Met [15] , PKB␣ [16] , and 17␤-HSD type-1 [17] were used during PCR reactions as previously described. The PCR primer sequences are listed in Table 1 . Each reaction also contained 1-5 Ci of [␣-32 P]dCTP and 0.5 U AmpliTaq Gold polymerase in 1ϫ PCR buffer II. Gene-specific cycles of PCR (GeneAmp 2400 thermocycler, Perkin Elmer Cetus) were run as follows: (1) 17␤-HSD and P450arom: 25 cycles: 94ЊC, 1 min; 55ЊC, 1 min; 72ЊC 2 min; (2) c-Met and PKB␣: 28 cycles: 94ЊC, 45 sec; 60ЊC, 45 sec; 72ЊC, 1 min. Both thermocycler protocols were terminated with a 10-min extension phase at 72ЊC. All RT-PCR reactions included a negative control in which no RNA was added. The amplification of all target mRNAs was determined to be linear with respect to increasing concentrations of RNA (1, 2, 5, 10, and 20 g/reaction), using the above indicated cycle numbers.
Primers designed to amplify a specific 194-bp region of the cDNA for the rat ribosomal protein, L19, were included in each PCR reaction [13] . This provided an internal control for differences in total RNA concentration among samples and variability among individual PCR amplifications. This method reflects a direct correlation between RNA concentration and L19 levels using the aforementioned PCR cycles, as has been demonstrated in our preliminary studies (not shown) and published reports by others using immature rat GC [13] .
To validate the effectiveness of each set of oligonucleotide primers in amplifying the desired target rat cDNA sequence, a preliminary RT-PCR reaction was performed using GC RNA. In this experiment, the P450arom, 17␤-HSD, c-Met, and PKB␣ PCR products were digested with restriction endonucleases. Specific restriction endonucleas- es were chosen that selectively cleaved each mRNA product into two smaller fragments of known base pair sizes.
All PCR products were visualized via electrophoresis using 2% agarose gels stained with ethidium bromide. For semiquantitative studies, the individual bands were cut from the gels and counted in a ␤-spectrometer. The cpm present in the bands representing 17␤-HSD, P450arom, PKB␣, and c-Met mRNAs were normalized to the cpm in the L19 mRNA bands for each treatment. Relative mRNA abundance is presented in this report as the ratio of target gene/L19 in arbitrary units.
Statistical Analyses
Treatments were administered in duplicate in all studies. All experiments were repeated a minimum of three times. Mean values from independent experiments were statistically analyzed by unpaired t-test and multiple comparisons were performed using one-way ANOVA followed by Tukey's test. Values were determined to be significant when P Ͻ 0.05.
RESULTS
The Effects of HGF on Estrogen Synthesis in GC
The effect of HGF on FSH-dependent E 1 and E 2 production. Results showed that FSH (0.3 and 3.0 ng/ml) increased E 2 over control levels. The stimulatory actions of FSH were suppressed by HGF (Fig. 1a) ; but importantly, FSH-stimulated E 1 production was not diminished by HGF (Fig. 1b) . This novel finding indicates that FSH-supported 17␤-HSD expression and/or activity is blocked by HGF, thereby disrupting the enzymatic conversion of E 1 into E 2 . In order to better define these steroid data, 17␤-HSD and P450arom mRNA levels were evaluated by semiquantitative RT-PCR.
The effect of HGF on 17␤-HSD and P450arom mRNA expression. As shown in Fig. 2, FSH (0.3, 3 .0, and 30 ng/ ml) stimulated the basal level of 17␤-HSD (Fig. 2a) and P450arom (Fig. 2b) mRNAs. Hepatocyte growth factor did not significantly alter the basal amount of P450arom and 17␤-HSD mRNAs. However, FSH-supported 17␤-HSD mRNA content was significantly reduced by HGF (Fig. 2a) , and this effect correlated with the suppressive effect of HGF on FSH-dependent E 2 , but not E 1 , accumulation. Surprisingly, FSH-stimulated P450arom mRNA content was also impaired by HGF (Fig. 2b) , and this observation somewhat contradicts the data showing that FSH-dependent E 1 accumulation was not attenuated by HGF. Such results raise several questions as to the effect of HGF on 17␤-HSD and P450arom protein in GC as FSH-dependent E 1 production was not blocked.
The effect of HGF on Bu 2 -cAMP-stimulated E 2 synthesis and expression of 17␤-HSD and P450arom mRNAs. Results showed that Bu 2 -cAMP (50, 100, and 250 M) stimulated the synthesis of E 2 when compared to control GC (Fig. 3) . However, HGF did not suppress Bu 2 -cAMP-supported E 2 production (Fig. 3) . Because Bu 2 -cAMP-dependent E 2 production was not attenuated by HGF, E 1 concentrations were not measured in these cultures.
Because the addition of Bu 2 -cAMP overcame the suppressive actions of HGF on E 2 synthesis in GC, the effect of HGF on Bu 2 -cAMP-stimulated P450arom and 17␤-HSD mRNA expression was also examined. As shown in Fig. 4 , HGF did not significantly change Bu 2 -cAMP-supported 17␤-HSD and P450arom mRNA levels in GC. Collectively, the preceding data indicate that HGF affects one or more sites of FSH-stimulated cAMP production, but nothing is presently known about the molecular regulatory mechanisms used by HGF in GC. The available evidence shows that c-Met is the first step in HGF signal transduction; therefore, the regulation of c-Met mRNA expression was examined in GC.
Modulation of c-Met mRNA Expression in GC by FSH, HGF, and Bu 2 -cAMP
Initial studies compared the effects of FSH, HGF, and Bu 2 -cAMP on c-Met mRNA expression at 48 h (Fig. 5a,b) . As shown in Fig. 5a , c-Met mRNA levels were reduced in the presence of FSH (0.3, 3.0, and 30 ng/ml) or HGF (30 ng/ml) when compared to control GC. No significant difference in c-Met mRNA content was measured when comparing the suppressive effect of FSH versus that of HGF (Fig. 5a) .
Cyclic AMP is a predominant second messenger that is stimulated by FSH. Because FSH caused a reduction in cMet mRNA, the ability of a cAMP analogue (Bu 2 -cAMP) to alter c-Met expression was investigated. Data revealed that Bu 2 -cAMP (100, 250, and 500 M) stimulated a significant increase in c-Met mRNA content when compared to control (Fig. 5b , 0 M Bu 2 -cAMP) or FSH-treated GC (Fig. 5a ) at 48 h in vitro.
Time-course. In order to investigate changes in c-Met expression during the early course of GC differentiation in vitro, a detailed time-course study was conducted (Fig. 6) . The relative abundance of c-Met mRNA in control GC did not change between t ϭ 0 and 12 h. However, when compared to freshly isolated GC (t ϭ 0) and the 12-h cultures, c-Met mRNA levels were increased at 24 and 48 h.
In GC that were challenged with HGF, c-Met mRNA content was not different from controls at 12 h (Fig. 6) . When compared to control GC, HGF caused a precipitous decline in c-Met mRNA content at 24 h, and this suppressive action was also detected at 48 h.
Dibutyryl-cAMP significantly augmented c-Met mRNA accumulation over that measured in control GC at 12 h in vitro (Fig. 6, 100 M concentration shown) . However, at 12 h, c-Met mRNA content was not different in Bu 2 -cAMP- or HGF-treated GC. When compared to the 12-h cultures, no additional increase in c-Met mRNA was induced by Bu 2 -cAMP at 24 and 48 h. However, in contrast to either the control GC or GC challenged with HGF, c-Met mRNA content was elevated at 24 and 48 h in the presence of Bu 2 -cAMP.
The above studies have shown that c-Met mRNA content is distinctly modulated by FSH, HGF, and Bu 2 -cAMP. The HGF-dependent signaling molecules have not been reported in GC. However, others have demonstrated that HGF stimulation is coupled with c-Met and PKB signal transduction. As an initial step in linking HGF with PKB in GC, regulation of PKB mRNA expression was investigated.
Regulation of PKB␣ mRNA by HGF
Using RT-PCR, our initial studies detected the mRNA for the three known PKB isoforms (␣, ␤, and ␥) in preparations of whole ovarian cell dispersates from immature rats (Zachow, unpublished observations). Subsequent screening by RT-PCR revealed that PKB␣ mRNA was observed in GC cultures (Fig. 7: 1096 bp, lane 1, control; lane 2, FSH) . Although PKB␤ and PKB␥ were not detected (not shown), the presence of PKB␤ and PKB␥ in GC cannot be discounted. If HGF uses PKB␣ as a signaling molecule in GC, it follows that PKB␣ mRNA expression can be modulated by HGF in GC. At 12, 24, 36, and 48 h in vitro, the relative abundance of PKB␣ mRNA was not different between control GC and those cells challenged with FSH (Fig. 8) . In control and FSH-stimulated GC, PKB␣ mRNA content increased at 12 h, relative to mRNA levels detected in t ϭ 0 GC. In the presence and absence of FSH, PKB␣ mRNA declined significantly at 24 h and 36 h, but mRNA levels rose sharply at 48 h (Fig. 8) .
In HGF-stimulated GC, a similar biphasic temporal pattern of PKB␣ mRNA accumulation was observed. However, when compared to control and FSH-stimulated GC, at 12, 36, and 48 h, the HGF challenge resulted in a significantly greater relative level of PKB␣ mRNA (Fig. 8) .
DISCUSSION
Hepatocyte growth factor can down-modulate ovarian steroidogenesis at two critical levels: de novo androgen synthesis in theca cells [6] and the conversion of androgen (i.e., androstenedione) into E 2 in GC. This study has extended this information by showing that HGF suppresses FSH-dependent E 2 synthesis while suppressing the expression of P450arom and 17␤-HSD mRNAs in rat GC. Based upon our steroid hormone and mRNA data, HGF exerts multiple levels of control within the estrogen biosynthetic pathway. Specifically, the FSH-stimulated aromatization of androstenedione into E 1 was not attenuated; whereas, the metabolism of E 1 into E 2 appears to have been blocked by HGF. Although not directly tested, this would indicate that 17␤-HSD activity is impaired. Because the levels of 17␤-HSD and P450arom mRNA were each reduced by HGF at 48 h in vitro, we suggest that sufficient translation and activity of P450arom protein occurred prior to 48 h. By this selective action, the P450arom-mediated conversion of androstenedione into E 1 would not be disrupted by HGF. A previous report has demonstrated that HGF reduces FSHstimulated P450arom activity in DES-primed rat GC in vitro [9] , thus indicating that the aromatization of androstenedione into E 1 can be blocked by HGF. Importantly, the effect of DES (e.g., substantially elevated estrogen concentrations) upon the molecular regulation of HGF activity in GC is unpredictable. That is, the selective targeting of P450arom versus 17␤-HSD by HGF may be affected by the presence or absence of estrogens.
Stimulation by FSH is arguably central to regulating GC function within selected and recruited follicles. Folliclestimulating hormone induces the sequential activation of (1) stimulatory G proteins (G s proteins), (2) adenylyl cyclasedirected generation of cAMP, and (3) cAMP-dependent protein kinases. Although HGF suppressed FSH-dependent E 2 production, HGF did not impair E 2 synthesis in the presence of the cAMP analogue, Bu 2 -cAMP. Similarly, Bu 2 -cAMP-stimulated expression of P450arom, and 17␤-HSD mRNAs were not attenuated by HGF. One explanation of these data is that HGF interferes with the FSH-induced cAMP pathway prior to the generation of cAMP. In fact, cytokine regulation at G s proteins and adenylyl cyclase has been indicated in GC [18, 19] . Alternatively, HGF could mobilize G i proteins, as has been demonstrated in cultured rat hepatocytes [20] . In so doing, the FSH-directed activation of adenylyl cyclase, cAMP production, and ultimately estrogen production would be collectively prevented. The involvement of G i proteins as an inhibitory mechanism would also be overcome by the addition of Bu 2 -cAMP. Because nothing is currently known about HGF signal transduction in GC, further studies are required in order to determine any interactions between HGF and the FSH-cAMP pathway in GC.
Based upon the observed effects of HGF in GC, as reported in this study and others [9] , HGF functions as a negative modulator of GC steroidogenic differentiation. If operational in young growing follicles in vivo, this HGFdirected action would be beneficial in preventing an untimely rise in E 2 secretion by GC. However, suppression of E 2 production by HGF would have to be reversible so that E 2 secretion would rise during the preovulatory phase of the cycle. In theory, HGF bioactivity could be neutralized by one or more of the following mechanisms: (1) downregulation in the synthesis of intraovarian HGF, (2) a reduction in c-Met expression and/or autophosphorylation, or (3) interruption of post-c-Met signal transduction. First, consider regulation of c-Met as a potential mechanism. In bovine follicles, c-Met mRNA concentrations increased in direct relation to follicle size [9] . This observation would suggest that down-regulation of c-Met is not involved in reversing HGF bioactivity in GC. The present report has shown that the relative level of c-Met mRNA in GC cultures is in fact regulated by FSH, HGF, and Bu 2 -cAMP. As observed at 12 h in vitro, c-Met mRNA levels were increased by either Bu 2 -cAMP or HGF but not FSH (not shown). Whereas at 48 h, the stimulatory effect of Bu 2 -cAMP was preserved; however, FSH and HGF each caused a precipitous decline in the amount of c-Met mRNA. These experimental observations suggest that several mechanisms can alter c-Met expression during GC differentiation, all of which warrant further investigation. For example, the HGFdependent increase in c-Met mRNA early on (e.g., 12 h in vitro) could be a primary event in establishing a key link between HGF and intracellular coupling that dampens FSHdirected E 2 synthesis. Whereas, once the HGF signaling machinery is operational, an HGF-directed negative feedback loop could down-modulate c-Met expression (e.g., 48 h in vitro). By this proposed mechanism, a sustained block in FSH-induced E 2 synthesis would be prevented in GC should HGF concentrations remain unchallenged in mature (preovulatory) follicles.
An interesting observation was that FSH (a potent stimulator of cAMP signal transduction) reduced the level of cMet mRNA in GC, but Bu 2 -cAMP induced a rapid and sustained elevation of c-Met mRNA content in vitro. This paradox is perhaps best rationalized when considering that FSH can signal via cascades in addition to that mediated by cAMP. For example, FSH can activate mitogen-activated protein kinase and tyrosine kinase pathways in GC [13, 21, 22] . Therefore, the opposite actions of FSH and Bu 2 -cAMP on c-Met expression implies that multiple FSH-dependent signaling molecules can selectively up-and down-modulate c-Met expression in GC. Because the cAMP analogue increased c-Met expression (present study), and c-Met mRNA was increased relative to follicle size in bovine GC [9] , it appears that the cAMP-rich environment in preovulatory follicles fosters c-Met gene expression. Any effects of FSH and HGF on the pattern of c-Met protein and tyrosine kinase activity in GC remain to be determined.
Interactions between c-Met activity and signaling molecules in GC have not been investigated. However, in nonovarian cells, HGF stimulates the activation of c-Met and phospholipid-dependent cascades [7] and PKB [12] . In that HGF stimulated PKB␣ mRNA accumulation, a preliminary link between HGF and PKB has been identified in GC. Interestingly, at 12 h in vitro, HGF up-regulated an increase in both PKB␣ mRNA and c-Met mRNA. One compelling interpretation of this observation is that during GC steroidogenic differentiation, HGF establishes two components of its signaling apparatus: c-Met and PKB␣.
In forming a physiologic model for HGF during GC growth and differentiation, the collective constituents of the follicular microenvironment must be considered. For example, insulin-like growth factor-I (IGF-I) and transforming growth factor-␤ (TGF␤) are present in young follicles [23, 24] . In vitro, IGF-I and TGF␤ each augment FSH-dependent E 2 production in GC [25, 26] and therefore can be considered antagonists of HGF. With this evidence in hand, we hypothesize that HGF functions as part of a negative modulatory cytokine system. This system could postpone the steroidogenic differentiation of GC that would otherwise be induced by combinations of FSH, IGF-I, and TGF␤. Therein, a precocious and reproductively detrimental increase in E 2 secretion would be blocked, and experimental evidence supports a role for HGF in this fundamental model.
